BLOG

biospace

With Positive Phase II Results, Cerevance Proves Concept in Parkinson’s

Private drug discovery company Cerevance reported positive clinical trial results Thursday for CVN424, an experimental treatment for Parkinson’s disease. The drug was discovered using Cerevance’s NETSseq platform, which holds potential for Parkinson’s treatments as well as many other diseases caused by transcriptional genetic errors.